IMCR:NASDAQ, Immunocore Holdings plc
IMCR stock overview
Immunocore Holdings plc (IMCR:NASDAQ) closed at $26.41 on November 20, 2026,
down 0.83% on the day.
The stock trades 35.1% below its 52-week high of $40.72
and 3.1% above its 52-week low of $25.61.
Over the past year, it lost 32.9%.
Immunocore Holdings plc is part of the Health Care sector.
Key figures
- Price
- $26.41
- Day change
- -0.83%
- Volume
- 546,182
- Average volume
- 447,495
- Market cap
- 1B+
- 52-week range
- $25.61 – $40.72
- 50-day average
- $30.49
- 200-day average
- $31.49
Price action over the past year
In 252 trading sessions since November 20, 2025, IMCR closed higher on 116 days (46%).
Its best day was October 20, 2026 (+9.25%) and its worst was April 21, 2026 (-6.17%).
It never moved 10% or more in a single session.
Recent signals
IMCR news
-
Nov 9, 2026:
Immunocore to present at upcoming investor conferences
-
Nov 6, 2026:
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma
-
Nov 6, 2026:
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
-
Nov 6, 2026:
Immunocore reports third quarter financial results and provides a business update
-
Oct 29, 2026:
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
-
Oct 29, 2026:
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
-
Oct 29, 2026:
Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?
-
Oct 17, 2026:
GeneDx Holdings And 2 Other Top Healthcare Stocks
About Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Similar stocks
Find more stocks like IMCR with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.